

MAY 04 1990

THE

# CANCER LETTER

P.O. Box 15189 WASHINGTON, D.C. 20003 TELEPHONE 202-543-7665

Vol. 16 No. 18  
May 4, 1990

(c)Copyright 1990 Cancer Letter Inc.  
Price \$195 Per Year US, Canada.  
\$220 Per Year Elsewhere

## NCI Moves To Suspend Researcher Amid Charges Contractor Made Mortgage And Other Payments

NCI has moved to suspend a researcher in the Laboratory of Tumor Cell Biology following allegations that a laboratory contractor paid for painting of his home and made several of his mortgage payments.

NIH Acting Director William Raub said NCI has proposed suspending Syed Zaki Salahuddin indefinitely, pending resolution of a federal grand jury investigation. Salahuddin, who has been under investigation by federal authorities for over a year, has not been formally charged with  
(Continued to page 2)

### In Brief

#### Elion Elected Member Of National Academy; Bleyer Heads M.D. Anderson Pediatrics

GERTRUDE ELION, scientist emeritus at Burroughs Wellcome, has been elected a member of the National Academy of Sciences. Elion, a Nobel laureate, has served as an outside advisor to NIH, most recently as a member of the National Cancer Advisory Board and a member of the so-called Lasagna committee, officially known as the National Committee to Review Current Procedures for Approval of New Drugs for Cancer and AIDS. . . . ARCHIE BLEYER, professor of pediatrics at Univ. of Washington, has been appointed head of the Div. of Pediatrics at Univ. of Texas M.D. Anderson Cancer Center. Bleyer said he plans to expand the use of innovative and aggressive therapies for leukemias and sarcomas, such as spinal perfusion and autologous bone marrow transplantation. . . . SUPREME COURT Justice Sandra Day O'Connor will address the annual meeting of the American Roentgen Ray Society, scheduled for May 14-18 at the Sheraton Washington Hotel in Washington. For information or registration, contact the society at 703/648-8910. . . . MAYO COMPREHENSIVE Cancer Center in Rochester, NY, is to host the annual meeting of the Assn. of American Cancer Institutes, scheduled for June 21-22. Registration deadline is June 1. Contact Robert Gluek, 507/284-2511. . . . BOARD OF SCIENTIFIC Counselors of NCI's Div. of Cancer Etiology is scheduled to meet June 21-22, in NIH Bldg. 31 Rm 10. The meeting is open at 1 p.m. on June 21, 9 a.m. on June 22. . . . ASSESSMENT OF PDQ as a Model System to Disseminate Information About Effective Therapy, RFP NCI-CO-03886-59 is temporarily delayed, according to NCI's Research Contracts Branch. The RFP will be available around May 21. All prospective offerors who have previously submitted a request in writing will receive a copy when available. For more information contact Christine Virts, 301/496-8628.

House Committee  
Proposes \$750 Mil.  
Increase For NIH,  
Supports Bypass

. . . Page 4

New Centers Plan  
Discussed By NCAB,  
Directors Committees

. . . Page 5

Washington Braces  
For Oncologists: It's  
The Spring Meetings

. . . Page 6

New Publications

. . . Page 7

NIH Workshop On  
Animal Care Planned

. . . Page 8

## NCI Researcher Says Firm Paid For Painting, Mortgage, On Home

(Continued from page 1)

any wrongdoing. He has seven working days to appeal the suspension from NCI, during which time he is on non-duty paid status.

According to Raub, last week Salahuddin told NCI Div. of Cancer Etiology Director Richard Adamson that Pan Data Systems, a company cofounded by his wife, Firoza, had paid for the painting of the Salahuddins' home and had made several mortgage payments on the home in 1987 or 1988.

Last year, when news of the investigation by the General Accounting Office and the HHS Inspector General became public, the researcher said that he had no financial stake in the company, which is located in Rockville, MD (*The Cancer Letter*, July 21, 1989).

At that time Salahuddin said that his wife was one of the company's founders in 1984, but left later that year. A statement by the company confirmed that account and added that Firoza Salahuddin had returned to the company from October 1985 to July 1986, when the relationship ended. "PDS noted that there is nothing improper in a government researcher having a scientific and friendship relationship with a company or its officials, and discussing information of common interest," the company's statement said. "At no time did Zaki Salahuddin have an ownership interest in PDS" (*The Cancer Letter*, Aug. 4, 1989).

According to federal investigators testifying as witnesses before the House Subcommittee on Oversight and Investigations this week, Salahuddin was involved in evaluating Pan Data's proposal for a subcontract while his wife worked at the firm. In addition, the investigators said, the researcher personally participated in the firm's business affairs, steered business in the firm's direction, and, according to

documents filed with government agencies by the firm, both he and his wife were listed as owners and directors of the company.

Salahuddin was required to file annual financial disclosure forms with NIH, but none of the statements he filed indicated ownership or other proprietary interest in Pan Data, the investigators said.

Attorneys for Salahuddin and for Pan Data could not be reached for comment by *The Cancer Letter's* press time this week.

According to Raub, Salahuddin said the mortgage payments and painting were "compensation for services Mrs. Salahuddin had performed as a founder for Pan Data."

The House subcommittee, chaired by Rep. John Dingell (D-MI), began investigating the allegations last year after it learned that a General Accounting Office inquiry had been stopped and turned over to the HHS Inspector General. The U.S. Attorney in Baltimore also is investigating the case.

The results of the subcommittee's inquiry were made public last week in testimony given by Clark Hall, one of three GAO investigators put on detail to the subcommittee. It is the first time any specific allegations have been voiced by any of the government entities investigating Salahuddin.

Hall testified that Pan Data, which was started in 1984, had 1988 sales of \$3 million. The largest percentage of its NIH contracts came from the Laboratory of Tumor Cell Biology, where Salahuddin is employed as a retrovirologist. The laboratory is headed by Robert Gallo.

In FY 1989, the laboratory accounted for 78 percent of NIH's total acquisitions from Pan Data, or \$713,000.

"Our evidence shows that the success of this company appears to be associated with Salahuddin's hands-on direction and management while he was employed at NIH," Hall said. "Zaki Salahuddin and his wife both had extensive involvement with the management, ownership and direction of Pan Data Systems."

The allegations Hall made included:

►Salahuddin provided training to Pan Data employees in how to market the firm's products.

►Salahuddin represented Pan Data at sales meetings with prospective clients, including negotiations with the U.S. Army and an Army contractor for an AIDS laboratory testing subcontract.

►In early 1985, Salahuddin suggested to Steve Josephs, a colleague at the laboratory, that Pan Data could provide needed computer services. Josephs then placed a purchase order for up to \$9,999 in

### THE CANCER LETTER

Editor: Jerry D. Boyd

Associate Editors:

Kirsten B. Goldberg, Patricia Williams

Editorial/Subscriptions Office

PO Box 15189, Washington, DC 20003

Tel: (202) 543-7665 Fax: (202) 543-6879

ISSN 096-3917. Published 48 times a year by The Cancer Letter Inc., also publisher of *The Clinical Cancer Letter* and *AIDS Update*. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, or transmitted in any form (electronic, mechanical, photocopying, facsimile, or otherwise) without prior written permission of the publisher. Violators risk criminal penalties and \$50,000 damages.

computer services from Pan Data.

►In 1985, Salahuddin commented to Flossie Wong-Staal (the former chief of the Molecular Genetics of Hematopoietic Cells Section, who has since left NCI) that Pan Data had "good people" and should be used in the future. Wong-Staal had previously placed a purchase order for up to \$9,999 for data handling and analysis services from Pan Data.

►While working at NCI, Salahuddin referred four individuals to Pan Data for employment.

►The Salahuddins are listed "frequently and prominently in official Pan Data Systems documents filed with various government agencies" apparently from the company's beginning. Salahuddin was one of two persons authorized to have access to the company's post office box in Kensington, MD, before the firm's incorporation.

Pan Data's Articles of Incorporation, filed in April 1984, show that Firoza Salahuddin owned 1,000 shares of stock in the corporation, out of a total of 4,000 shares issued, and was a director of the company, Hall testified.

In August 1984, the Salahuddins resigned as directors of the company, according to minutes of a shareholders' meeting, Hall said. However, corporate minutes submitted by the firm to the Small Business Administration in November 1984 listed both Zaki and Firoza Salahuddin each as 20 percent owners, and said that Zaki Salahuddin was an owner and director of corporate development. Firoza Salahuddin was referred to alternately as a Pan Data president, chairman of the board, and secretary.

The Salahuddins each submitted a statement to SBA pledging their intent to contribute \$12,500 to Pan Data if necessary to maintain the company, the subcommittee investigation found.

Subpoenaed bank records show that Pan Data issued checks to the Salahuddins, Hall testified. One check to Firoza Salahuddin for \$2,500 was noted as an "advance director's fee." Other checks to her were for \$200 and \$400, and checks to Zaki Salahuddin were for \$67.72 and \$430.

Other bank records indicate that the Salahuddins pledged to support \$105,000 of a \$150,000 loan to Pan Data, the subcommittee investigation found. Salahuddin identified himself as an officer or partner in the company in bank documents he submitted in July 1986. A notation also lists the Salahuddins as 25 percent owners. A bank memorandum in September 1986 indicates that the company's ownership had changed and that the Salahuddins' personal guarantee is no longer required, Hall said.

According to Hall's testimony, Gallo told the

investigators that he had heard that Salahuddin was involved with the company and in late 1986, confronted the researcher. Salahuddin told Gallo that his wife was an employee of the company and assured him that she would end her employment, Hall said.

The subcommittee investigation also alleged that Pan Data profited from a virus discovered by Salahuddin and his NCI colleagues. According to Hall's testimony, in October 1986, Salahuddin, Dharam Ablashi and others isolated the human herpes virus 6, HHV6. Ablashi then trained a Pan Data employee to conduct assays to detect HHV6. Pan Data then sold the laboratory more than \$250,000 in HHV6 related products and services, beginning in November 1986.

Hall testified that from June through October 1988, Salahuddin and another NIH researcher, Phillip Markham, participated in the technical evaluation of two vendor proposals for an NIH subcontract to conduct HHV6 testing. Pan Data was one of the two vendors.

"As part of the technical evaluation, Salahuddin and Markham participated in site visits to Pan Data Systems," Hall said in his testimony. "Prior to participating in the technical evaluation, Salahuddin told the assistant project director that Pan Data Systems was the 'only competent lab' to perform the required assays." NIH awarded contracts to both firms for the project.

The subcommittee investigation also alleged that:

►Salahuddin purchased supplies at the NIH store using a credit card assigned to the Laboratory of Tumor Cell Biology. The supplies were then delivered to Pan Data's laboratory.

►A Pan Data employee made products in Salahuddin's section of the laboratory that the company then sold to other firms.

►When certain biological agents were unavailable at its own laboratory, Pan Data management instructed an employee to obtain the agents from Ablashi, a collaborator of Salahuddin's at NCI.

►Pan Data may have sold to other companies four vials of AIDS virus that were originally purchased by Salahuddin using funds from the NCI laboratory.

Hall testified that the subcommittee investigation turned up "certain weaknesses in administrative procedures and controls at Gallo's laboratory. These weaknesses may have resulted in the loss of hundreds of thousands of dollars worth of equipment and supplies, as well as contribute to the creation of an atmosphere where the employees were not safeguarding government assets." Among the findings were:

►Procedures for using the charge card at the NIH

supply store were lax. Anyone introduced to the purchasing agent as an employee could obtain the card and charge equipment and supplies. Staff members generally did not sign a log to identify users of the card. The subcommittee's review of charge slips using the card numbers assigned to the laboratory showed the signatures of 40 laboratory employees, five Pan Data employees, 46 other non-NIH individuals and other unidentifiable signatures.

▶Although NIH regulations require annual inventories, the most recent inventory in the laboratory prior to the subcommittee's investigation was completed in 1985. "Even then, we could not find evidence that existing shortages were properly reconciled," Hall said.

▶A recent inventory in the laboratory showed that more than \$275,000 in equipment was missing.

▶The inventory also disclosed a large number of overages; 285 pieces of equipment that were not listed in inventory records but were found in the laboratory.

▶Another weakness was the inability of NIH to secure Building 37 housing the laboratory. According to Hall, the front door frames were misaligned, making it impossible to lock the doors. During the investigation, NIH built a new set of outer doors to secure the building.

Raub testified that NIH and NCI have cooperated fully in the investigations and were told previously by the HHS Inspector General not to take any action in order not to disrupt the investigations. He testified that NIH now is taking the following actions "in an attempt to prevent future conflicts of interest in the award of subcontracts of the type alleged to have occurred":

1. All employees asked to review subcontracts will be required to sign a form stating that they have no conflict of interest with respect to the proposers and to obtain approval of the relevant senior official.

2. NIH will seek approval from HHS to incorporate a requirement in future prime contracts that all contractors or subcontractors have a standards of conduct/conflict of interest policy in place prior to receipt of award. Such a requirement would also be incorporated into existing contracts.

## **House Committee Proposes \$750 Mil. Increase For NIH; Supports Bypass**

The House Budget Committee has proposed adding \$750 million above inflation over the FY 1990 budget NIH, and has made a strong statement in support of NCI's bypass budget.

The proposal was contained in the committee's budget report, which was submitted to the full House

last week. A vote on the report is scheduled for this week.

The committee also recommended a \$1 billion increase in AIDS funding, for a total of \$2.95 billion, a 50 percent increase over the 1990 budget. The committee recommendation also for the first time targets \$143 million for pediatric AIDS cases.

The committee report said the increase for NIH, which excludes AIDS funding, should be used for research in cancer, Alzheimer's disease and heart disease, but also indicated that even more funds should be allocated to NCI.

### **Cancer 'Not Adequately Funded'**

"The committee is especially concerned that the nation's commitment to eradicating cancer is not adequately funded," the report said. "While we have made tremendous progress over the past two decades in cancer research, in order to address the full spectrum of this epidemic that kills 500,000 Americans annually, basic and applied research, prevention and control, education and detection, and construction programs will require substantial increases if we are to meet our commitment in finding effective cures and prevention tools for cancer.

**"It should be noted that even with the additional monies proved for NIH, the National Cancer Institute will fall short of cancer research goals presented in the bypass budget, and it is the intention of the committee to give attention to this area in the future."**

Rep. Barbara Boxer (D-CA), chairman of the committee's Human Resources Task Force, was instrumental in getting the higher funding amount and the language adopted in the committee report. Earlier this year, she held hearings around the country on areas of underfunded health care needs.

Boxer last week proposed an amendment to the report that would transfer an additional \$6 billion from military spending to be used for deficit reduction, and increases in health research, education and the environment. The House Rules Committee disallowed the move.

Nevertheless, Boxer's attempt brought praise from the cancer research community.

"Congresswoman Boxer is doing a really remarkable job for cancer research and all of biomedical research in the House Budget Committee," said John Grupenhoff, a Washington representative for the American Society of Clinical Oncology, the Assn. of American Cancer Institutes and other organizations.

AACI President Sydney Salmon and Karen Antman, chairman of the ASCO Public Issues Committee, met with Boxer in her office last week to discuss cancer

research and the funding implications of the Administration's budget.

"She told us then of her plans to push hard for a 'peace dividend,'" Grupenhoff said. "I believe that her work now is going to cause a significant shift in Congress to decrease military expenditures and have some of the money used for domestic purposes, including biomedical research.

"This couldn't come at a better time for ASCO members because they will be attending their annual meeting in Washington on May 20-22, just about the time appropriations decisions will be made in Congress; many cancer researchers here in Washington making visits and telephone calls to members of Congress to talk about the serious problems in funding of cancer research will give a strong push to the efforts Boxer is undertaking." (See related story on Page 6).

#### **'Imperative' That Biotech Lead Is Maintained**

The \$750 million, the committee report said, "is intended to increase funding for new and competing grants for biomedical research at the NIH.

"The United States is preeminent in biomedical research, and it is imperative that this edge be maintained. However, the United States spends over \$2,000 per person on health care expenditures each year and only \$35 per person for research into the causes and cures of diseases.

"The committee notes that training, grants, clinical trials, construction and intramural programs have been cut in the past. It is essential that all programs be properly funded to ensure stability and growth in medical research.

"Although the NIH budget has increased substantially over this decade, the number of new grants has declined. It is estimated that less than one out of four approved research grants will be funded by NIH this year.

"Many research facilities are outdated, and construction and new equipment are needed. Increased funding for biomedical research not only saves lives and improves the health of American people, but NIH's development of drugs, technologies and trained scientists is the foundation of this nation's growing biotechnology industry and promotes trade and competitiveness with other nations," the report concluded.

The report also recommended a \$201 million increase over the 1990 budget for the Alcohol, Drug Abuse & Mental Health Administration, and increased funding for Medicaid initiatives, including AIDS early intervention and AIDS disproportionate share hospitals.

The report also expressed concern about lack of research funds at the National Institute of Child Health & Human Development, and said the institute needs a "substantial budget increase." The report did not specify a dollar amount.

#### **New Draft of Centers Plan Discussed By NCAB, Directors Committees**

Evolution of the five year plan for the Cancer Centers Program continued this week with the National Cancer Advisory Board Centers Committee and the ad hoc Committee of Cancer Center Directors taking another whack at it.

Albert Owens, chairman of the ad hoc committee who drafted the previous version of the plan (*The Cancer Letter*, April 27), presented another draft which fleshed out suggestions made by joint committee members two weeks ago. The newest draft is 11 pages long, up from eight pages. The initial draft which was rejected by center directors was more than 50 pages.

The focal point of the plan remained unchanged, essentially: a statement of important cancer center activities, their current funding, and the amount needed to bring each up to the figures called for in NCI's 1991 fiscal year bypass budget.

The draft also calls for adequate staffing of NCI's Cancer Centers Branch and for "ongoing involvement of cancer center directors or their designees with NCI staff directing program planning and implementation."

A recommendation was added which states:

"Clearly, new administrative strategies will have to be devised in order to achieve the objectives of this five year plan. For example, it might well be useful to have each cancer center develop a five year plan of its own as an aid to national program planning and evaluation. Program initiatives and budget projections might be provided by centers as part of the annual bypass budget development process. Workshops, planning grants, and feasibility studies might serve to encourage initiatives in areas of special opportunity and need. More flexibility might well be provided to center directors through cancer center support grants to encourage the more rapid exploration of scientific opportunities and the translation of discoveries into effective medical practice. Again, it would be beneficial to have cancer center representatives participate actively as these strategies are drawn up."

Under a section entitled, "Strategies, Program Priorities, and Resources Required," Owens included this statement:

"Special opportunities currently exist for innovative

patient focused research designed to probe the fundamental biology of human tumorigenesis and to develop new means of cancer treatment and prevention. Cancer centers can play a key role in this work. Resources to support this research need to be set aside, and special-review and funding mechanisms will probably be required to ensure efficient program implementation."

"That's a zinger," exclaimed ad hoc committee member Phillip Sharp. "It calls for a set aside for cancer treatment and prevention, with a special study section for review." He suggested that "if that's what you mean," greater emphasis should be placed on that recommendation.

Participating in this session of the joint committee were NCAB Centers Committee Chairman John Durant and members Enrico Mihich and Irene Pollin; ad hoc committee members Owens, Sharp, Alan Sartorelli, and Walter Eckhart; and NCI staff members Alan Rabson, Judith Whalen, and Alan Schreier.

## Washington Braces For Oncologists Invasion: It's The Spring Meetings

The invasion of the oncologists--nurse, surgical, medical, laboratory--will hit Washington DC beginning May 15 and continuing through May 26. It is the annual consecutive (concurrent in some cases) meetings of five cancer professional societies, with most of the sessions scheduled for the Washington Convention Center.

From 15,000 to 20,000 members of those societies will be attending the meetings. Each are at or near all time highs in membership, and all will probably set records for annual meeting attendance.

This will be the last time, at least for a few years, when the largest of the societies, the Oncology Nursing Society, will meet prior to the others in the same city. ONS decided a few years ago that its requirements for meeting space and facilities does not always coincide with that of the American Society of Clinical Oncology and American Assn. for Cancer Research, and has made its separate arrangements. ASCO and AACR will meet in Houston next year.

ONS, which will be staging its 15th annual congress with the theme, "Monumental Steps for Oncology Nursing 1975-1990," will open May 15 with two days of pre-congress sessions. These will include "Congress to Congress," a discussion of health policy issues followed by visits to members of Congress; "Oncology in the 90s: Future Directions;" "Practical Considerations for Preparing Grants;" and a variety of clinically related and scientific sessions.

The Oncology Nursing Certification Examination will be given on May 16. This will include recertification for those who passed the exam when it was first given and now need to be recertified.

Abstract and instructional sessions will be held throughout the day May 17-19, except during the annual business meeting May 18. An ONS/ASCO joint education workshop is scheduled for Sunday, May 20 in which symposia will be presented on metastatic breast cancer, infusional therapy, bone marrow transplantation, sexual dysfunction and rehabilitation, and payment for clinical trials.

Dolores Esparza is outgoing ONS president.

ASCO'S 26th annual meeting will open May 20 and will be held concurrently with the annual meetings of the Society of Clinical Oncology and the Society of Head and Neck Surgeons.

Fourteen symposia and special interest topics will make the educational program May 20 and the meet the professor sessions will be held May 20, 21, and 22, with each session repeated once.

Robert Young will present his presidential address May 21, followed by the Karnofsky Lecture, plenary session, and annual business meeting.

Scientific sessions will be held May 21 and 22, and the annual ASCO/AACR joint symposium will be held May 23 with presentations by Bert Vogelstein, "Molecular Approaches to Clinical Cancer;" Jeffrey Sklar, "Lymphomas;" Vogelstein, "Molecular Approaches to Colorectal Cancer;" and Dennis Slamon, "Breast Cancer."

Women in Cancer Research, a new organization affiliated with ASCO and AACR, will sponsor a reception May 22; hold its business meeting May 24; and put on a panel discussion, "NIH Grants: What You Need to Know" May 24.

AACR had invited President George Bush to address the meeting May 23, in which AACR President Harris Busch would have had the opportunity to crack a few Bush to Bush jokes. George Bush could not make it, however.

AACR's Scientific and Public Education Committee has scheduled a legislative update May 23. Other special sessions, interspersed among the scientific presentations, include:

--Plenary session 2, "Endogenous Hormones and Cancer," chaired by Malcolm Pike.

--Plenary session 3, "Epidermal Growth Factor Receptors in Malignancy," chaired by John Mendelsohn.

--Symposium 1, "Cancer Chemoprevention: Present and Future," chaired by Lee Wattenberg.

--Symposium 2, "Recent Developments in Breast Cancer Research," chaired by Ruth Sager.

--Symposium 3, "Human Tumor Associated Antigens: Molecular Profile and Clinical Applications," chaired by Ingegerd Hellstrom.

--Symposium 4, "Novel Molecular Events in the Cell Cycle," chaired by Arthur Pardee.

--Symposium 5, "New Developments in Experimental and Human Pancreatic Cancer," chaired by Parviz Pour.

--Symposium 6, "Antisense Oligonucleotides as Regulators of Gene Expression," chaired by Jack Cohen.

--Symposium 7, "Papillomaviruses and Human Cancer," chaired by Janet Butel.

--Symposium 8, "Extracellular Matrix Regulation of Growth and Gene Expression," chaired by Lola Reid.

--Symposium 9, "Cytokines: Their Biology and Potential for Regulation," chaired by Joost Oppenheim.

--Symposium 10, "Effects of Glucocorticoid Receptors on Cell Growth and Gene Expression," chaired by Brad Thompson.

--Symposium 11, "Metastasis: Genetic Mechanisms and Cytokine Signal Transduction," chaired by Lance Liotta and Garth Nicolson.

--Symposium 12, "c-fps, c-jun, and Other Nuclear Binding Factors," chaired by Robert Franza.

--Symposium 13, "Endogenous versus Exogenous Factors as Major Cancer Risk Determinants," chaired by Bruce Ames.

--Symposium 14, "Multidrug Resistance in the Laboratory and the Clinic," chaired by Michael Gottesman.

--Methods Workshop 1, "The Polymerase Chain Reaction: Its Subtleties and Applications," chaired by Bernard Poiesz.

--Methods Workshop 2, "Introducing Genes into Mammalian Cells with Retroviral Vectors," chaired by James Zweibel.

A symposium organized by the Committee on Minority Issues will be held on "Career Opportunities in Basic and Clinical Cancer Research," chaired by Carol Moore.

Busch's presidential address, to be delivered May 24, is titled, "The Final Common Pathway of Cancer."

The annual business meeting will be held May 24.

**Society of Surgical Oncology** and **Society of Head and Neck Surgeons** sessions will be held concurrently with ASCO meetings May 20-22. Those registered for either of the three organizations may attend sessions of the others without additional registration or fees.

SSO presents four annual awards:

<> Lucy Wortham James Laboratory Basic Research

award will be presented to Michael Wigler, Cold Spring Harbor Laboratory, who will speak on "Oncogenes and Cellular Signal Transduction," May 20, 3 p.m., Convention Center room 3233.

<> Lucy Wortham James Clinical Research award will go to Denis Burkitt, London, whose topic is titled, "Possible Prevention of Cancer of Western Culture," May 21, 11:45 a.m., Convention Center room 3233.

<> James Ewing Lecture, by Walter Lawrence, Medical College of Virginia, "Concerns about Clinical Trials," May 22, 10 a.m., Convention Center room 3233.

<> James Ewing Layman's award, posthumously to Rose Kushner. The award will be accepted by her husband, Harvey, at the annual Presidential Banquet at the Hyatt Regency Capitol Hill on the evening of May 21.

SSO President Benjamin Rush will deliver his Presidential Address May 20, 11 a.m., Convention Center room 3233. It is entitled, "Whether, Wither, Whither Oncology Surgeons."

**Society of Head and Neck Surgeons** present one award, the Hayes Martin Lecture. It will be given this year by Alando Ballantyne, M.D. Anderson Cancer Center, titled, "Reflections of a Cancer Observer."

SHNS President M.J. Jurkiewicz will deliver his Presidential Address May 21, 10 a.m., Convention Center room 2022. It is titled, "Head and Neck Surgery: Preservation."

*Award winners for ONS, ASCO, and AACR have previously been announced in The Cancer Letter.*

## New Publications

Fifteen new NCI Oncology Overview titles have been published recently. These are specialized bibliographies with abstracts, each referencing 150 to 500 recent publications on a cancer topic of high current interest, drawn from more than 3,000 sources.

Leading researchers in the field covered by each Overview review and select the most relevant and significant abstracts for each topic.

The Overviews are available by single copy from the Government Printing Office. Following are the latest titles and their document numbers:

"Newer Radionuclide Imaging Techniques in Oncology: PET and SPECT," Lee Adler, editor. \$5. No. 017-042-00271-1.

"Late Sequelae of Cancer Therapy in Children and Adolescents, G.J. D'Angio, editor. \$4.75. No. 017-042-00270-2.

"Hyperthermia Alone and In Conjunction with

"Other Modalities," Dennis Leeper, editor. \$8. No. 017-042-00274-5.

"Paraneoplastic Syndromes," Larry Nathanson, editor. \$5.50. No. 017-042-00273-7.

"Mammography," Faith Rachofsky, editor. \$3.25. No. 017-042-00272-9.

"Environmental Tobacco Smoke and Cancer," William Weiss, editor. \$2.75. No. 017-042-00265-6.

"Mutagenic Photoproducts," Eugene LeClerc, editor. \$2.75. No. 017-042-00267-2.

"Recent Epidemiologic Studies of Neoplasms Among Asians," Haitung King and Frances Locke, editors. \$6. No. 017-042-00266-4.

"Biological Markers of Carcinogen Exposure," John Groopman, editor. \$4.50. No. 017-042-00268-1.

"Carcinogenic Products Formed During Cooking or Processing, and Inadvertent Contaminants in Food," John Weisburger, editor. \$6. No. 017-042-00269-9.

"Liposomes as Carriers of Antineoplastic Agents and Immunomodulators," Eric Mayhew and D. Papahadjopoulos, editors. \$8. No. 017-042-00263-0.

"Hematopoietic Growth Factors," Malcolm Moore, editor. \$8. No. 017-042-00261-3.

"Transmembrane Signal Transduction," Catherine O'Brian, editor. \$10. No. 017-042-00260-5.

"Genetic Intervention: Gene Transfer, Gene Therapy and Gene Modification," Martin Cline, editor. \$8.50. No. 017-042-00262-1.

"Viral Transactivation," Michael Karin, editor. \$8. No. 017-042-00264-8.

Visa and MasterCard are accepted and checks for orders may be made payable to the Superintendent of Documents and mailed to: Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402. The document number should be referenced.

#### ACCC Publications

The Assn. of Community Cancer Centers has available the following publications:

"Cancer DRGs: A Comparative Report On Key Cancer DRGs," Third Edition. Presents information about cancer and cancer related DRGs, to assist cancer programs in planning and development. Worksheets enable cancer program managers to calculate average profit or loss by cancer DRG for their institution and to make comparisons with national averages. Cost is \$225 per copy for general ACCC members, \$250 for nonmembers.

"Oncology Issues: The Journal of Cancer Program Management," subscriptions for nonmembers are \$40 a year; \$60 per year for institutions and medical libraries.

"Community Cancer Programs In the United States,"

a reference guide to approximately 400 freestanding and hospital based cancer programs, providing information on cancer therapies, staff contacts and special services. \$50 each.

For ordering information contact ACCC, 11600 Nebel St. Suite 201, Rockville, MD 20852.

#### Other Publishers

"Access Device Guidelines," on the use of catheters, implanted ports and reservoirs, and pumps are available from the Oncology Nursing Society. Each can be purchased separately, for \$4 each for ONS members, \$5 nonmembers, or as a set for \$10 ONS members, \$13 nonmembers. Module I, "Catheters"; Module II, "Implanted Ports and Reservoirs"; Module III, "Pumps." Contact Publications Dept., ONS, 1016 Greentree Rd., Pittsburgh, PA 15220, phone 412/921-7373.

"Consensus Development Conference on Oral Complications of Cancer Therapies: Diagnosis, Prevention and Treatment," a monograph based on proceedings of an NIH Consensus Conference held in April 1989, is available at no charge by writing to National Institute of Dental Research, P.O. Box 54793, Washington, D.C. 20032.

"Triumph: Getting Back to Normal When You Have Cancer," by Marion Morra, assistant director of the Yale Comprehensive Cancer Center, and medical writer Eve Potts. \$9.95 U.S., \$11.95 Canada, plus \$1 for postage and handling for each book ordered. Avon Books, Dept. BP, Rte. 2, Dresden, TN 38255.

## NIH Announces Workshops On Care And Use Of Laboratory Animals

The NIH Office of Protection from Research Risks is sponsoring a series of workshops on implementing the Public Health Service policy on human care and use of laboratory animals.

The workshops are open to institutional administrators, members of animal care and use committees, laboratory animal veterinarians, investigators and other institutional staff who have responsibility for high quality management of institutional animal care and use programs.

A workshop is scheduled for May 8-9, in San Juan, Puerto Rico. For information and registration, contact Susan Schwartz, assistant professor, Caribbean Primate Research Center, Univ. of Puerto Rico, Medical Science Campus, PO Box 1053, Sabana Seca, Puerto Rico 00749, phone 809/784-6619. For more information contact Roberta Sonneborn, Executive Assistant for Animal Welfare Education, NIH, Bldg 31 Rm 5B59, Bethesda, MD 20892, phone 301/496-7163.